Adverse effects of semaglutide compared to liraglutide: an integrative literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/33181 |
Resumo: | Introduction: The treatment for obesity has shown great evolution in recent years. Liraglutide and semaglutide are drugs that act on weight loss, contributing to avoid the metabolic consequences that overweight can cause. As with all drugs, both have side effects, which influence treatment adherence. Objective: To search the literature for adverse reactions of semaglutide compared to liraglutide when used for weight loss. Methodology: The Cochrane Library, PubMED, LILACS, and CAPES databases were searched using the following keywords: "GLP-1", "adverse effects", "safety", "weight loss", "liraglutide", and "obesity", selecting articles in English and Portuguese published in the last 5 years. Reviews, meta-analyses, monographs, dissertation theses, books, incomplete articles, and studies whose population sample consisted of diabetics or that evaded the theme were excluded. Results: A final sample of 12 articles was selected. The main side effects in users of GLP-1 analogues were concentrated in the gastrointestinal system, namely nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal pain. Other systems also showed side symptoms, although at a lower frequency, such as central nervous system, cardiovascular, renal, and hepatic, as well as psychiatric events. The vast majority of the studies were conducted in adult participants, with only 1 in a sample of children. Few cases were classified as severe, with most symptoms being mild or moderate. Final Considerations: The use of semaglutide seems to be linked to side effects, especially in the gastrointestinal tract, of greater intensity when compared to liraglutide. However, weight loss was shown to be greater in semaglutide users. |
id |
UNIFEI_c65b0f6fdc5f7d832101e395cd5d4723 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/33181 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Adverse effects of semaglutide compared to liraglutide: an integrative literature reviewEfectos adversos de la semaglutida en comparación con la liraglutida: una revisión bibliográfica integradoraEfeitos adversos da semaglutida comparada à liraglutida: uma revisão integrativa de literaturaAdverse effectsWeight lossLiraglutide.Efectos adversosPérdida de pesoLiraglutida.Efeitos adversosEmagrecimentoLiraglutida.Introduction: The treatment for obesity has shown great evolution in recent years. Liraglutide and semaglutide are drugs that act on weight loss, contributing to avoid the metabolic consequences that overweight can cause. As with all drugs, both have side effects, which influence treatment adherence. Objective: To search the literature for adverse reactions of semaglutide compared to liraglutide when used for weight loss. Methodology: The Cochrane Library, PubMED, LILACS, and CAPES databases were searched using the following keywords: "GLP-1", "adverse effects", "safety", "weight loss", "liraglutide", and "obesity", selecting articles in English and Portuguese published in the last 5 years. Reviews, meta-analyses, monographs, dissertation theses, books, incomplete articles, and studies whose population sample consisted of diabetics or that evaded the theme were excluded. Results: A final sample of 12 articles was selected. The main side effects in users of GLP-1 analogues were concentrated in the gastrointestinal system, namely nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal pain. Other systems also showed side symptoms, although at a lower frequency, such as central nervous system, cardiovascular, renal, and hepatic, as well as psychiatric events. The vast majority of the studies were conducted in adult participants, with only 1 in a sample of children. Few cases were classified as severe, with most symptoms being mild or moderate. Final Considerations: The use of semaglutide seems to be linked to side effects, especially in the gastrointestinal tract, of greater intensity when compared to liraglutide. However, weight loss was shown to be greater in semaglutide users.Introducción: El tratamiento de la obesidad ha presentado una gran evolución en los últimos años. La liraglutida y la semaglutida son fármacos que actúan sobre la pérdida de peso, contribuyendo a evitar las consecuencias metabólicas que puede provocar el sobrepeso. Como todo fármaco, ambos presentan efectos colaterales, los cuales influyen en la adhesión al tratamiento. Objetivo: buscar en la literatura cuáles son las razones adversas de la semaglutinación, en comparación con la liraglutinación, cuando se utiliza para fines de reducción de peso. Metodología: Se realizaron búsquedas en las bases de datos Cochrane Library, PubMED, LILACS y CAPES utilizando las siguientes palabras clave: "GLP-1", "adverse effects", "safety", "weight loss", "liraglutide" y "obesity", seleccionando artículos en inglés y portugués publicados en los últimos 5 años. Se excluyeron las revisiones, los meta-análisis, las monografías, las tesis doctorales, los libros, los artículos incompletos y los estudios cuya muestra poblacional estaba formada por diabéticos o que evadían el tema. Resultados: Se seleccionaron doce artículos como muestra final. Los principales efectos secundarios en los usuarios de análogos del GLP-1 se concentraron en el sistema gastrointestinal, a saber, náuseas, vómitos, dispepsia, estreñimiento, diarrea y dolor abdominal. Otros sistemas también mostraron síntomas secundarios, aunque con una frecuencia menor, como el sistema nervioso central, el cardiovascular, el renal y el hepático, además de los eventos psiquiátricos notificados. La gran mayoría de los estudios se llevaron a cabo en participantes adultos, y sólo 1 tenía una muestra infantil. Pocos casos se clasificaron como graves, la mayoría de los síntomas fueron leves o moderados. Consideraciones finales: El uso de semaglutida parece estar relacionado con efectos secundarios, especialmente en el tracto gastrointestinal, de mayor intensidad en comparación con liraglutida. Sin embargo, la pérdida de peso demostró ser mayor en los usuarios de semaglutida.Introdução: O tratamento para a obesidade tem apresentado grande evolução nos últimos anos. A liraglutida e a semaglutida são medicamentos que atuam na perda de peso, contribuindo para evitar as consequências metabólicas que o excesso de peso pode causar. Como todo fármaco, ambas apresentam efeitos colaterais, os quais influenciam na adesão ao tratamento. Objetivo: buscar na literatura quais as reações adversas da semaglutida, em comparação à liraglutida, quando utilizadas para fins de redução de peso. Metodologia: Buscou-se nas bases de dados Cochrane Library, PubMED, LILACS e CAPES pelos seguintes descritores: “GLP-1”, “adverse effects”, “safety”, “weight loss”, “liraglutide” e “obesity”, selecionando artigos em inglês e em português, publicados nos últimos 5 anos. Foram excluídas revisões, metanálises, monografias, teses de dissertação, livros, artigos incompletos e estudos cuja amostra populacional fosse composta por diabéticos ou que apresentassem fuga ao tema. Resultados: Foram selecionados 12 artigos como amostra final. Os principais efeitos colaterais em usuários de análogos de GLP-1 se concentraram no sistema gastrointestinal, sendo eles náusea, vômitos, dispepsia, constipação intestinal, diarreia e dores abdominais. Outros sistemas também apresentaram sintomas colaterais, mesmo que em menor frequência, tais como sistema nervoso central, cardiovascular, renal e hepática, além de serem relatados eventos psiquiátricos. A grande maioria dos estudos foram realizados em participantes adultos, sendo que apenas 1 teve como amostra um público infantil. Poucos casos foram classificados como graves, sendo a maioria dos sintomas leves ou moderados. Considerações Finais: O uso da semaglutida parece estar interligado a efeitos colaterais, principalmente no trato gastrointestinal, de maiores intensidades, quando comparado à liraglutida. No entanto, a perda de peso se mostrou maior em usuários de semaglutida.Research, Society and Development2022-08-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3318110.33448/rsd-v11i10.33181Research, Society and Development; Vol. 11 No. 10; e579111033181Research, Society and Development; Vol. 11 Núm. 10; e579111033181Research, Society and Development; v. 11 n. 10; e5791110331812525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/33181/28101Copyright (c) 2022 Ana Laura Silva Machado de Moraes; Beatriz Schiavoni Vilela; Bruna Cardoso Souza; Isadora de Figueiredo Infante Falleiros ; Izabella Lara Pereira ; Jheovanna Silva Oliveira Ribeiro https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMoraes, Ana Laura Silva Machado de Vilela, Beatriz Schiavoni Souza, Bruna Cardoso Falleiros , Isadora de Figueiredo Infante Pereira , Izabella Lara Ribeiro , Jheovanna Silva Oliveira 2022-08-12T22:23:03Zoai:ojs.pkp.sfu.ca:article/33181Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:54.557362Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review Efectos adversos de la semaglutida en comparación con la liraglutida: una revisión bibliográfica integradora Efeitos adversos da semaglutida comparada à liraglutida: uma revisão integrativa de literatura |
title |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
spellingShingle |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review Moraes, Ana Laura Silva Machado de Adverse effects Weight loss Liraglutide. Efectos adversos Pérdida de peso Liraglutida. Efeitos adversos Emagrecimento Liraglutida. |
title_short |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
title_full |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
title_fullStr |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
title_full_unstemmed |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
title_sort |
Adverse effects of semaglutide compared to liraglutide: an integrative literature review |
author |
Moraes, Ana Laura Silva Machado de |
author_facet |
Moraes, Ana Laura Silva Machado de Vilela, Beatriz Schiavoni Souza, Bruna Cardoso Falleiros , Isadora de Figueiredo Infante Pereira , Izabella Lara Ribeiro , Jheovanna Silva Oliveira |
author_role |
author |
author2 |
Vilela, Beatriz Schiavoni Souza, Bruna Cardoso Falleiros , Isadora de Figueiredo Infante Pereira , Izabella Lara Ribeiro , Jheovanna Silva Oliveira |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Moraes, Ana Laura Silva Machado de Vilela, Beatriz Schiavoni Souza, Bruna Cardoso Falleiros , Isadora de Figueiredo Infante Pereira , Izabella Lara Ribeiro , Jheovanna Silva Oliveira |
dc.subject.por.fl_str_mv |
Adverse effects Weight loss Liraglutide. Efectos adversos Pérdida de peso Liraglutida. Efeitos adversos Emagrecimento Liraglutida. |
topic |
Adverse effects Weight loss Liraglutide. Efectos adversos Pérdida de peso Liraglutida. Efeitos adversos Emagrecimento Liraglutida. |
description |
Introduction: The treatment for obesity has shown great evolution in recent years. Liraglutide and semaglutide are drugs that act on weight loss, contributing to avoid the metabolic consequences that overweight can cause. As with all drugs, both have side effects, which influence treatment adherence. Objective: To search the literature for adverse reactions of semaglutide compared to liraglutide when used for weight loss. Methodology: The Cochrane Library, PubMED, LILACS, and CAPES databases were searched using the following keywords: "GLP-1", "adverse effects", "safety", "weight loss", "liraglutide", and "obesity", selecting articles in English and Portuguese published in the last 5 years. Reviews, meta-analyses, monographs, dissertation theses, books, incomplete articles, and studies whose population sample consisted of diabetics or that evaded the theme were excluded. Results: A final sample of 12 articles was selected. The main side effects in users of GLP-1 analogues were concentrated in the gastrointestinal system, namely nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal pain. Other systems also showed side symptoms, although at a lower frequency, such as central nervous system, cardiovascular, renal, and hepatic, as well as psychiatric events. The vast majority of the studies were conducted in adult participants, with only 1 in a sample of children. Few cases were classified as severe, with most symptoms being mild or moderate. Final Considerations: The use of semaglutide seems to be linked to side effects, especially in the gastrointestinal tract, of greater intensity when compared to liraglutide. However, weight loss was shown to be greater in semaglutide users. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-11 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33181 10.33448/rsd-v11i10.33181 |
url |
https://rsdjournal.org/index.php/rsd/article/view/33181 |
identifier_str_mv |
10.33448/rsd-v11i10.33181 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33181/28101 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 10; e579111033181 Research, Society and Development; Vol. 11 Núm. 10; e579111033181 Research, Society and Development; v. 11 n. 10; e579111033181 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052770038054912 |